$651 Million is the total value of Octagon Capital Advisors LP's 40 reported holdings in Q3 2023. The portfolio turnover from Q2 2023 to Q3 2023 was 75.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| APLS | Buy | APELLIS PHARMACEUTICALS INC | $119,065,200 | -50.1% | 3,130,000 | +19.5% | 18.29% | -44.9% |
| Buy | ROIVANT SCIENCES LTD | $51,006,560 | +29.6% | 4,367,000 | +11.9% | 7.84% | +43.1% | |
| IMVT | New | IMMUNOVANT INCput | $38,390,000 | – | 1,000,000 | +100.0% | 5.90% | – |
| INSM | Buy | INSMED INC | $32,421,000 | +318.7% | 1,284,000 | +249.9% | 4.98% | +362.1% |
| APLS | New | APELLIS PHARMACEUTICALS INCput | $25,677,000 | – | 675,000 | +100.0% | 3.94% | – |
| ETNB | Buy | 89BIO INC | $18,823,784 | -6.9% | 1,219,157 | +14.3% | 2.89% | +2.8% |
| VRDN | Buy | VIRIDIAN THERAPEUTICS INC | $16,369,974 | -25.4% | 1,067,143 | +15.6% | 2.52% | -17.7% |
| APLS | New | APELLIS PHARMACEUTICALS INCcall | $15,216,000 | – | 400,000 | +100.0% | 2.34% | – |
| Buy | AN2 THERAPEUTICS INC | $13,950,606 | +127.7% | 867,575 | +20.3% | 2.14% | +151.2% | |
| New | AMYLYX PHARMACEUTICALS INC | $12,725,450 | – | 695,000 | +100.0% | 1.96% | – | |
| TSHA | New | TAYSHA GENE THERAPIES INC | $8,777,778 | – | 2,777,778 | +100.0% | 1.35% | – |
| GOSS | Buy | GOSSAMER BIO INC | $6,818,869 | +43.6% | 8,187,883 | +106.9% | 1.05% | +58.5% |
| New | DIANTHUS THERAPEUTICS INC | $6,561,600 | – | 480,000 | +100.0% | 1.01% | – | |
| PMVP | Buy | PMV PHARMACEUTICALS INC | $5,550,560 | +88.7% | 904,000 | +92.3% | 0.85% | +108.6% |
| INZY | Buy | INOZYME PHARMA INC | $5,460,000 | +1872.3% | 1,300,000 | +2515.6% | 0.84% | +2051.3% |
| ANNX | Buy | ANNEXON INC | $4,838,000 | -17.2% | 2,050,000 | +23.5% | 0.74% | -8.6% |
| GLUE | Buy | MONTE ROSA THERAPEUTICS INC | $3,893,767 | +2756.4% | 812,895 | +3984.9% | 0.60% | +3047.4% |
| CNTA | Buy | CENTESSA PHARMACEUTICALS PLCsponsored ads | $3,077,132 | +20.7% | 475,600 | +15.5% | 0.47% | +33.2% |
| TVTX | New | TRAVERE THERAPEUTICS INCcall | $2,682,000 | – | 300,000 | +100.0% | 0.41% | – |
| CBAY | New | CYMABAY THERAPEUTICS INCput | $894,600 | – | 60,000 | +100.0% | 0.14% | – |
| New | BIONOMICS LIMITEDads | $453,600 | – | 168,000 | +100.0% | 0.07% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2023-11-14
Signatures
The EDGAR filing(s) were signed by:
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| APELLIS PHARMACEUTICALS INC | 12 | Q3 2023 | 33.2% |
| ARCUS BIOSCIENCES INC | 12 | Q3 2023 | 18.1% |
| CELLDEX THERAPEUTICS INC NEW | 12 | Q3 2023 | 10.1% |
| GOSSAMER BIO INC | 12 | Q3 2023 | 6.2% |
| 4D MOLECULAR THERAPEUTICS IN | 10 | Q1 2023 | 6.6% |
| BRIDGEBIO PHARMA INC | 10 | Q3 2023 | 6.6% |
| AVIDITY BIOSCIENCES INC | 10 | Q1 2023 | 3.8% |
| VERA THERAPEUTICS INC | 9 | Q2 2023 | 3.5% |
| DYNE THERAPEUTICS INC | 9 | Q3 2023 | 3.5% |
| STOKE THERAPEUTICS INC | 9 | Q2 2023 | 3.7% |
View Octagon Capital Advisors LP's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-06 |
| SC 13G/A | 2024-02-05 |
| SC 13G | 2024-02-05 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-15 |
| 13F-HR | 2023-02-14 |
| SC 13G | 2023-01-25 |
| 13F-HR | 2022-11-14 |
View Octagon Capital Advisors LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.